New obesity drug combo enters early human testing
NCT ID NCT06151964
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new drug combination (AZD9550 and AZD6234) for weight loss in 166 adults who are overweight or obese, with or without type 2 diabetes. The main goals are to check safety, tolerability, and how the drug moves through the body. It is an early-stage trial, so it focuses on finding the right dose and ensuring the drug is safe before testing if it works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AZD9550 (a dual GCG/GLP-1 receptor agonist) and AZD6234 (a SARA)
What this could lead to
If successful, this could lead to a new weight-loss treatment that also helps control blood sugar in people with type 2 diabetes.
What could go wrong
This is an early Phase 1/2 trial focused on safety and dosing, not effectiveness. The drug may cause side effects or fail to show meaningful weight loss in later studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVERWEIGHT AND OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Graz, 8036, Austria
-
Research Site
Vienna, 1090, Austria
-
Research Site
Surrey, British Columbia, V3T 4G8, Canada
-
Research Site
Hamilton, Ontario, L8L 5G8, Canada
-
Research Site
Sarnia, Ontario, N7T 4X3, Canada
-
Research Site
Stouffville, Ontario, L4A 1H2, Canada
-
Research Site
Toronto, Ontario, M4G 3E8, Canada
-
Research Site
Sherbrooke, Quebec, J1L 0H8, Canada
-
Research Site
Magdeburg, 39120, Germany
-
Research Site
Neu-Ulm, 89231, Germany
-
Research Site
Neuss, 41460, Germany
-
Research Site
Fukuoka, 812-0025, Japan
-
Research Site
Shinjuku-ku, 160-0004, Japan
-
Research Site
Suita-shi, 565-0853, Japan
-
Research Site
Uppsala, 752 37, Sweden